Search

Author/Creator Schirripa, M

2. 774PThe role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. (23rd October 2018)

Authors:
Orsi, G; Andrikou, K; Bergamo, F; Nappo, F; Manai, C; Passardi, A; Puzzoni, M; Vallarelli, S; Libertini, M; Riggi, M L; Pugliese, G; Zaniboni, A; Schirripa, M; Procaccio, L; Silvestris, N; Scartozzi, M; Casadei Gardini, A; Zagonel, V; Cascinu, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LBA22Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. (23rd October 2018)

Authors:
Morano, F; Corallo, S; Di Bartolomeo, M; Lonardi, S; Cremolini, C; Rimassa, L; Sartore Bianchi, A; Murialdo, R; Zaniboni, A; Adamo, V; Tomasello, G; Tampellini, M; Fanchini, L; Schirripa, M; Clavarezza, M; Petrelli, F; Longarini, R; Cinieri, S; de Braud, F G M; Pietrantonio, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P-207Clinico-pathological and molecular characterization of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. (20th June 2018)

Authors:
Schirripa, M; Biason, P; Cortiula, F; Pino, M; Urbano, F; Antoniotti, C; Corallo, S; Gelsomino, F; Orlandi, A; Lonardi, S; Bergamo, F; Munari, G; Malapelle, U; Rugge, M; Mescoli, C; Reggiani Bonetti, L; Lanza, G; Dei Tos, A; De Maglio, G; Zagonel, V
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P-237Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (20th June 2018)

Authors:
Dell'Aquila, E; Pantano, F; Rossini, D; Stellato, M; Lonardi, S; Masi, G; Schirripa, M; Marmorino, F; Antoniotti, C; Murgioni, S; Tomasello, G; Ronzoni, M; Racca, P; Vincenzi, B; Allegrini, G; Urbano, F; Buonadonna, A; Banzi, M; Tonini, G; Cremolini, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P-237Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (20th June 2018)

Authors:
Dell'Aquila, E; Pantano, F; Rossini, D; Stellato, M; Lonardi, S; Masi, G; Schirripa, M; Marmorino, F; Antoniotti, C; Murgioni, S; Tomasello, G; Ronzoni, M; Racca, P; Vincenzi, B; Allegrini, G; Urbano, F; Buonadonna, A; Banzi, M; Tonini, G; Cremolini, C
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search